Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban